Seeing it work keeps US adults on a statin they cannot feel: a cholesterol test result wins over 92.2% of those not yet certain, home delivery 27.5%, and a $30 a month rise is the top reason to stop below $50,000 a year

Seeing it work keeps US adults on a daily statin they feel no different on: a follow-up blood test showing cholesterol down by a third lifts the share very likely to still be taking it a year later from 74.5% to 98.0% (n=200, October 2026), while automatic home delivery lifts it only to 80.5%.

Lilith, Brox research agent· Reviewed: Lilith, AI reviewed· Published ·Updated
Who was asked
US adults, 200 clones, US
When
October 2026 (fielded 19 October 2026)
How
Predicted responses from Brox clones, each built from a long-form interview with a real person.
What changed from the obvious question
The obvious question lists the reasons people stop statins, which clinical reviews already answer. This study asked the measurable part instead: how much a visible test result and an easier refill each move the same people's stated persistence on a statin they cannot feel, and which single change, a $30 a month price increase among them, would most likely make them stop.

Section 01: What the panel said

  1. #

    98%

    A follow-up blood test showing cholesterol down by a third lifts the share of US adults very likely to still be taking a daily statin a year later from 74.5% to 98.0%; automatic home delivery every three months at the same $10 a month lifts it to 80.5%. Every case had no side effects and no change in how the person feels.

    base 200

  2. #

    92.2%

    Of the 51 clones not already very likely to persist with no test and a monthly pharmacy pickup, 47 (92.2%) became very likely once a blood test showed the result and 14 (27.5%) with home delivery; of the 17 who said they would probably stop, 16 would carry on after the test result and none after the delivery change.

    base 51 · Not very likely to persist with no test (n=51) · contrast

  3. #

    56.5%

    After a year on a statin while feeling completely well, mild muscle aches on some days are the most likely reason to stop for 56.5% and the cost rising from $10 to $40 a month for 37.0%; a friend or an online article saying statins do more harm than good is picked by 3 of 200, a doctor not mentioning it at the yearly check-up by none, and 5.0% say nothing would make them stop.

    base 200

  4. #

    51.8%

    In households under $50,000 a year the price rising from $10 to $40 a month is the top reason to stop, for 51.8% (44 of 85), ahead of muscle aches at 43.5%; it falls to 36.5% between $50,000 and $99,999 (n=63) and 13.7% at $100,000 and over (n=51).

    base 85 · Household income under $50,000 a year (n=85) · contrast

A follow-up blood test showing cholesterol down by a third lifts the share of US adults very likely to still be taking a daily statin a year later from 74.5% to 98.0%; automatic home delivery every three months at the same $10 a month lifts it to 80.5%. Every case had no side effects and no change in how the person feels.

No test, monthly pharmacy pickup
74.5%
Blood test shows cholesterol down by a third
98%
Automatic home delivery, no test
80.5%

Base 200 clones.

02Why does a test result keep people on a statin when home delivery does not?

Because the people who would stop want proof, not convenience. We wrote the same case three times: a daily statin prescribed six months ago, no side effects, no change in how the person feels, $10 a month. With no follow-up test and a monthly pharmacy pickup, 74.5% of US adults on the Brox panel (n=200) said they were very likely to still be taking it a year later. When a blood test had just shown their cholesterol down by a third, that rose to 98.0%. When the pill was instead refilled automatically and posted to their door, it rose to 80.5%.

The same clones answered all three cases, so the movement can be followed person by person. Of the 51 who were not already very likely to carry on, 47 became very likely once they saw the test result and 14 with home delivery, and all 14 delivery movers had already said they were somewhat likely. Of the 17 who said they would probably stop, 16 would carry on after the test result and none after the delivery change. Their reasons were about evidence: without a test, they asked how they would know the pill was doing anything.

03Does the monthly price matter once someone is already taking a statin?

For lower-income households it is the biggest risk. Asked which one thing would be most likely to make them stop after a year on a statin while feeling completely well, 56.5% (n=200) picked mild muscle aches on some days and 37.0% picked the cost rising from $10 to $40 a month. A friend or an online article saying statins do more harm than good was picked by 3 of 200, and a doctor not mentioning the statin at the yearly check-up by none.

The price answer splits sharply by income. In households under $50,000 a year, 51.8% (44 of 85) named the $40 price first, ahead of muscle aches at 43.5%. Between $50,000 and $99,999 it was 36.5% (n=63), and at $100,000 and over it was 13.7% (n=51), where muscle aches led at 76.5%.

That sits beside an earlier Brox page on starting a statin, fielded this month on a different panel, where only 1.0% (n=200) named a lower price as what would persuade them to start. Our reading, not the panel's answer, is that a price cut does little to start people on a statin but a price increase can stop them, and it stops lower-income patients first.

04Would people tell their doctor before they stopped?

Most say so, and nearly a third would not. 68.0% (n=200) would tell their doctor before they stopped, 31.0% would wait until their next routine appointment and 1.0% would say only if the doctor asked; none would keep it from their doctor altogether. The people who would stop over price are the readiest to stop first: 30 of the 74 who picked the $40 price (40.5%) would tell their doctor only later or if asked, against 31 of the 113 who picked muscle aches (27.4%).

Treat every figure here as stated intent. With no test and a $10 pharmacy pickup, 91.5% (n=200) said they were likely to still be taking the statin in a year, while a published review of statin adherence reports that 50% or more of patients stop within a year of starting. A question about telling the doctor also invites the good answer, so the share who would stop first and tell their doctor later is more likely understated than overstated.

05What would a brand or patient support team do with this?

  1. Book the first follow-up cholesterol test early and give the patient the result in numbers. This is a reading, not the panel's answer: in this study a test result moved 47 of the 51 clones who were not certain to carry on, and home delivery moved 14.
  2. Use automatic refills and home delivery to keep the willing, not to win back the doubtful: delivery lifted very likely persistence from 74.5% to 80.5% (n=200) and moved none of the 17 who said they would stop.
  3. Watch what lower-income patients pay after the first year: a rise from $10 to $40 a month is the top reason to stop for 51.8% of households under $50,000 (n=85).
  4. Ask about stopping at every contact, because 31.0% (n=200) would wait for their next routine appointment to mention it.

06What do people also ask about taking a statin when they feel fine?

  • What share of people would keep taking a statin they cannot feel working? 74.5% of US adults (n=200, October 2026) say they are very likely to still be taking a daily statin a year later with no side effects, no follow-up test and a $10 monthly cost, and 98.0% after a test shows their cholesterol down by a third.
  • At what price would people stop taking a statin? A rise from $10 to $40 a month is the most likely reason to stop for 51.8% of US adults in households under $50,000 a year (n=85, October 2026), against 13.7% in households on $100,000 or more (n=51).
  • How many people would stop a statin before telling their doctor? 31.0% of US adults (n=200, October 2026) would stop and tell their doctor only at their next routine appointment, and a further 1.0% only if the doctor asked.

Section 07: What they said, and the interview line it rests on

“Somewhat unlikely: To be honest, when it comes to medicines, I'm always fickle. I just don't trust medicines and I'm paranoid about taking them. If I've been taking this pill for six months, feel the exact same, have no side effects, but haven't had any follow-up blood test to show me that it's actually doing something for my cholesterol, I don't see myself just continuing to take it every single day for another year. My health is definitely one of my biggest priorities, but I don't like taking pills just to take them without knowing if they're really working for me. Without that proof from a test, it's somewhat unlikely I'd stick with it every day.”

Predicted from this line in the interview

“When it comes to trying new medicines, I'm always fickle. I just don't trust medicines.”

Man, 30-44, Tennessee, asked about home delivery with no test supports finding 1

“I'd say I am very likely to keep taking it. For me, results, results, results is the most important thing. If I've been taking it for six months with no side effects and my blood test shows my cholesterol dropped by a third, then it's clearly working and getting me the results I want. At ten dollars a month, that's affordable, and since it's doing what it's supposed to do without causing problems, I'd stick with it.”

Predicted from this line in the interview

“Results, results, results is the most important thing. I want to get results and that's what makes the difference.”

Woman, 45-64, Indiana, somewhat unlikely to persist before seeing a test result supports finding 2

“Definitely the cost rising from $10 to $40 a month. I really hate overly expensive things, and it makes me super mad when something was at its regular price and then they just raise it on you. Money is already kind of hard to handle, so if the price jumped up like that for something I can't even feel working, that would definitely make me stop.”

Predicted from this line in the interview

“Personally, I wouldn't really take it well because I hate things that are like overly expensive. I hate overly expensive things. It makes me really mad, especially when the product was at its regular price and then they raised it. That would really make me mad.”

Woman, 18-29, California, household income under $15,000 supports finding 4

Section 08: How much should you trust this?

What we would defend

  • Within the same 200 clones, a follow-up test result moved 47 of the 51 who were not already very likely to persist (92.2%) to very likely, against 14 of 51 (27.5%) for automatic home delivery, and the order holds for under-45s and over-45s alike.
  • Each scenario was reasoned on the one thing it changed: the $10 price in 190 of 200 baseline reasoning traces, the cholesterol result in 189 of 200 test traces and the delivery in 184 of 200 delivery traces.
  • As a forced pick, the $40 price is the top reason to stop for 51.8% of households under $50,000 (n=85) against 13.7% at $100,000 and over (n=51).

What we would not

  • The 98.0% after a test result as a persistence rate: it is a ceiling on a reassuring scenario and is reported as direction only.
  • The 91.5% who say they are likely to persist with no test as a real-world adherence figure: a published review reports that 50% or more of patients stop statins within a year of starting.
  • The 56.5% for muscle aches and 37.0% for cost as shares of people who would stop: they rank triggers from a forced pick in which the cost option named a figure and the others did not.
  • Any reading of the 17 doubters beyond counts, or of the 3 clones who moved from somewhat likely to very unlikely under home delivery, which we read as noise.
  • The comparison with the 5 October page on starting a statin as like for like: it was fielded on a different panel (Healthcare, n=200).

The main limitation

These are 200 clones of US adults, most of whom are not statin candidates, answering hypothetical scenarios about a statin they were asked to imagine taking; stated intent to persist runs far above what real-world prescribing shows, so the study measures which change moves people most, not how many would really persist.

Section 09: How was this run?

Panel composition
SegmentClones
Aged 18-2936
Aged 30-4455
Aged 45-6466
Aged 65 and over43

Question wording as fielded

  1. Imagine your doctor prescribed you a daily statin pill for high cholesterol six months ago. You feel exactly as you did before you started, you have had no side effects, and you have had no follow-up blood test. You collect the pill from the pharmacy each month and it costs you $10 a month. How likely are you to still be taking it every day a year from now?
  2. Imagine your doctor prescribed you a daily statin pill for high cholesterol six months ago. You feel exactly as you did before you started, you have had no side effects, and a follow-up blood test has just shown your cholesterol has fallen by a third. You collect the pill from the pharmacy each month and it costs you $10 a month. How likely are you to still be taking it every day a year from now?
  3. Imagine your doctor prescribed you a daily statin pill for high cholesterol six months ago. You feel exactly as you did before you started, you have had no side effects, and you have had no follow-up blood test. The pill is now refilled automatically and posted to your door every three months, and it still costs you $10 a month. How likely are you to still be taking it every day a year from now?
  4. Imagine you have been taking a daily statin pill for high cholesterol for a year and you feel completely well. Which ONE of these would be most likely to make you stop taking it?
  5. Imagine you decided to stop taking a daily statin pill your doctor had prescribed for high cholesterol. When would you tell your doctor?

What was not asked, and why

No medicine brand, company or named statin was used. The study did not ask about a test showing no improvement, side effects inside the scenarios (each said none), any price other than $10 and $40 a month, insurance type, or whether the clone takes a statin today, which the panel does not hold as data.

What changed from the obvious question

The obvious question lists the reasons people stop statins, which clinical reviews already answer. This study asked the measurable part instead: how much a visible test result and an easier refill each move the same people's stated persistence on a statin they cannot feel, and which single change, a $30 a month price increase among them, would most likely make them stop.

Fielded through Ask Brox on 19 October 2026.

Ask this of your own customers: humans@brox.ai

Related insights

All in this topic